Production of Soluble and Active Transferrin Receptor-targeting Single-chain Antibody Using Saccharomyces Cerevisiae

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2006 Mar 22

PMID 16550469

Citations 24

Authors

Benjamin J Hackel

Dagang Huang

Jennifer C Bubolz

Xin X Wang

Eric V Shusta

Affiliations

Soon will be listed here.

Abstract

Purpose: This study describes the soluble production, purification, and functional testing of an anti-transferrin receptor single-chain antibody (OX26 scFv) using the yeast Saccharomyces cerevisiae.

Methods: The yeast secretion apparatus was optimized by modulating expression temperature, the folding environment of the endoplasmic reticulum, and gene dosage. Secreted scFv was purified using immobilized metal affinity chromatography, and tested for binding and internalization into the RBE4 rat brain endothelial cell line.

Results: Secretion of OX26 scFv was optimal when expression was induced at 20 degrees C. Co-overexpression of heavy chain binding protein and protein disulfide isomerase elevated scFv expression levels by 10.4 +/- 0.3-fold. Optimization of scFv gene dosage increased secretion by 7.1 +/- 0.2-fold, but the overall benefits of binding protein and protein disulfide isomerase overexpression were diminished. Purified OX26 scFv yields of 0.5 mg/L secreted protein were achieved, and the scFv was actively internalized into RBE4 cells with a pattern similar to that observed with intact OX26 monoclonal antibody.

Conclusions: The optimized S. cerevisiae expression system is amenable to production of soluble and active brain targeting OX26 scFv, and the yeast-produced scFv has potential for the targeting and delivery of small molecules, proteins, or drug carriers across the blood-brain barrier (BBB).

Citing Articles

Mining yeast diversity unveils novel targets for improved heterologous laccase production in Saccharomyces cerevisiae.

Wong R, Foo M, Lay J, Wai T, Moore J, Dutreux F Microb Cell Fact. 2025; 24(1):60.

PMID: 40059166 PMC: 11892151. DOI: 10.1186/s12934-025-02677-1.

Heterologous (Over) Expression of Human SoLute Carrier (SLC) in Yeast: A Well-Recognized Tool for Human Transporter Function/Structure Studies.

Pochini L, Galluccio M Life (Basel). 2022; 12(8).

PMID: 36013385 PMC: 9410066. DOI: 10.3390/life12081206.

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up.

Madhavan A, Arun K, Sindhu R, Krishnamoorthy J, Reshmy R, Sirohi R Microb Cell Fact. 2021; 20(1):124.

PMID: 34193127 PMC: 8246677. DOI: 10.1186/s12934-021-01617-z.

Cell-surface engineering of yeasts for whole-cell biocatalysts.

Ye M, Ye Y, Du Z, Chen G Bioprocess Biosyst Eng. 2021; 44(6):1003-1019.

PMID: 33389168 DOI: 10.1007/s00449-020-02484-5.

Mining Data From Plasma Cell Differentiation Identified Novel Genes for Engineering of a Yeast Antibody Factory.

Koskela E, Gonzalez Salcedo A, Piirainen M, Iivonen H, Salminen H, Frey A Front Bioeng Biotechnol. 2020; 8:255.

PMID: 32296695 PMC: 7136540. DOI: 10.3389/fbioe.2020.00255.

References

Zhang Y, Pardridge W . Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke. 2001; 32(6):1378-84. DOI: 10.1161/01.str.32.6.1378. View

Feldhaus M, Siegel R, Opresko L, Coleman J, Feldhaus J, Yeung Y . Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol. 2003; 21(2):163-70. DOI: 10.1038/nbt785. View

Friden P, Walus L, Musso G, Taylor M, Malfroy B, Starzyk R . Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci U S A. 1991; 88(11):4771-5. PMC: 51748. DOI: 10.1073/pnas.88.11.4771. View

Shusta E, Holler P, Kieke M, Kranz D, Wittrup K . Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol. 2000; 18(7):754-9. DOI: 10.1038/77325. View

Robinson A, Bockhaus J, Voegler A, Wittrup K . Reduction of BiP levels decreases heterologous protein secretion in Saccharomyces cerevisiae. J Biol Chem. 1996; 271(17):10017-22. DOI: 10.1074/jbc.271.17.10017. View

Pardridge W . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1):3-14. PMC: 539316. DOI: 10.1602/neurorx.2.1.3. View

Zhang Y, Schlachetzki F, Zhang Y, Boado R, Pardridge W . Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther. 2004; 15(4):339-50. DOI: 10.1089/104303404322959498. View

Gietz R, Schiestl R, Willems A, Woods R . Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast. 1995; 11(4):355-60. DOI: 10.1002/yea.320110408. View

Sikorski R, Hieter P . A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics. 1989; 122(1):19-27. PMC: 1203683. DOI: 10.1093/genetics/122.1.19. View

10.

Wang X, Campoli M, Ko E, Luo W, Ferrone S . Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004; 294(1-2):23-35. DOI: 10.1016/j.jim.2004.08.005. View

11.

Poul M, Becerril B, Nielsen U, Morisson P, Marks J . Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000; 301(5):1149-61. DOI: 10.1006/jmbi.2000.4026. View

12.

Pardridge W, Eisenberg J, Yang J . Human blood-brain barrier insulin receptor. J Neurochem. 1985; 44(6):1771-8. DOI: 10.1111/j.1471-4159.1985.tb07167.x. View

13.

Roux F, DURIEU-TRAUTMANN O, Chaverot N, Claire M, Mailly P, Bourre J . Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol. 1994; 159(1):101-13. DOI: 10.1002/jcp.1041590114. View

14.

Nieba L, Honegger A, Krebber C, Pluckthun A . Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 1997; 10(4):435-44. DOI: 10.1093/protein/10.4.435. View

15.

Boado R, Ji A, Pardridge W . Cloning and expression in Pichia pastoris of a genetically engineered single chain antibody against the rat transferrin receptor. J Drug Target. 2001; 8(6):403-12. DOI: 10.3109/10611860008997916. View

16.

Parekh R, Shaw M, Wittrup K . An integrating vector for tunable, high copy, stable integration into the dispersed Ty delta sites of Saccharomyces cerevisiae. Biotechnol Prog. 1996; 12(1):16-21. DOI: 10.1021/bp9500627. View

17.

Butz J, Niebauer R, Robinson A . Co-expression of molecular chaperones does not improve the heterologous expression of mammalian G-protein coupled receptor expression in yeast. Biotechnol Bioeng. 2003; 84(3):292-304. DOI: 10.1002/bit.10771. View

18.

Gilbert H . Protein disulfide isomerase and assisted protein folding. J Biol Chem. 1997; 272(47):29399-402. DOI: 10.1074/jbc.272.47.29399. View

19.

Clements J, Catlin G, Price M, Edwards R . Secretion of human epidermal growth factor from Saccharomyces cerevisiae using synthetic leader sequences. Gene. 1991; 106(2):267-71. DOI: 10.1016/0378-1119(91)90209-t. View

20.

Olivier J, Huertas R, Lee H, Calon F, Pardridge W . Synthesis of pegylated immunonanoparticles. Pharm Res. 2002; 19(8):1137-43. DOI: 10.1023/a:1019842024814. View